Lupin Launches Pregnancy Prevention Drug Tydemy in US | CORPORATE ETHOS

Lupin Launches Pregnancy Prevention Drug Tydemy in US

By: | March 13, 2018
lupin

Mar 13: Mumbai-based drug maker Lupin Ltd on Tuesday announced the launch of its Tydemy Tablets (Drospirenone, Ethinyl Estradiol, Levomefolate Calcium, 3mg/0.03mg/0.451mg and Levomefolate Calcium, 0.451mg) in the US, having received an approval from the United States Food and Drug Administration (USFDA) earlier.

“Lupin’s Tydemy (Drospirenone, Ethinyl Estradiol, Levomefolate Calcium, 3mg/0.03mg/0.451mg & Levomefolate Calcium, 0.451mg) are the generic equivalents of Bayer HealthCare Pharmaceuticals Inc.’s Safyral tablets. It is indicated for use by women to prevent pregnancy and to raise folate levels in women who choose to use an oral contraceptive for contraception,” the company said in a statement.

“Drospirenone, EE, Levomefolate Calcium, 3mg/0.03mg/0.451mg & Levomefolate Calcium, 0.451mg tablets had annual sales of approximately USD 22 million in the US (IQVIA January 2018),” it added.

Lupin shares were trading at Rs 777.30, up 0.93% from the previous closing of Rs 770.10, on BSE at 2.03 pm today.